Ieva Kurilova1, Regina G H Beets-Tan2, Jessica Flynn3, Mithat Gönen3, Gary Ulaner4, Elena N Petre5, F Edward Boas5, Etay Ziv5, Hooman Yarmohammadi5, Elisabeth G Klompenhouwer6, Andrea Cercek7, Nancy A Kemeny7, Constantinos T Sofocleous8. 1. Department of Interventional Oncology/Radiology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. 2. Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. 3. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY. 4. Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 5. Department of Interventional Oncology/Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. 6. Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 7. Department of Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY. 8. Department of Interventional Oncology/Radiology, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: sofoclec@mskcc.org.
Abstract
INTRODUCTION: The purpose of this study was to identify predictors of overall (OS) and liver progression-free survival (LPFS) following Yttrium-90 radioembolization (RAE) of heavily pretreated patients with colorectal cancer liver metastases (CLM), as well as to create and validate a predictive nomogram for OS. MATERIALS AND METHODS: Metabolic, anatomic, laboratory, pathologic, genetic, primary disease, and procedure-related factors, as well as pre- and post-RAE therapies in 103 patients with CLM treated with RAE from September 15, 2009 to March 21, 2017 were analyzed. LPFS was defined by Response Evaluation Criteria In Solid Tumors 1.1 and European Organization for Research and Treatment of Cancer criteria. Prognosticators of OS and LPFS were selected using univariate Cox regression, adjusted for clustering and competing risk analysis (for LPFS), and subsequently tested in multivariate analysis (MVA). The nomogram was built using R statistical software and internally validated using bootstrap resampling. RESULTS: Patients received RAE at a median of 30.9 months (range, 3.4-161.7 months) after detection of CLM. The median OS and LPFS were 11.3 months (95% confidence interval, 7.9-15.1 months) and 4 months (95% confidence interval, 3.3-4.8 months), respectively. Of the 40 parameters tested, 6 were independently associated with OS in MVA. These baseline parameters included number of extrahepatic disease sites (P < .001), carcinoembryonic antigen (P < .001), albumin (P = .005), alanine aminotransferase level (P < .001), tumor differentiation level (P < .001), and the sum of the 2 largest tumor diameters (P < .001). The 1-year OS of patients with total points of < 25 versus > 80 was 90% and 10%, respectively. Bootstrap resampling showed good discrimination (optimism corrected c-index = 0.745) and calibration (mean absolute prediction error = 0.299) of the nomogram. Only baseline maximum standardized uptake value was significant in MVA for LPFS prediction (P < .001; SHR = 1.06). CONCLUSION: The developed nomogram included 6 pre-RAE parameters and provided good prediction of survival post-RAE in heavily pretreated patients. Baseline maximum standardized uptake value was the single significant predictor of LPFS.
INTRODUCTION: The purpose of this study was to identify predictors of overall (OS) and liver progression-free survival (LPFS) following Yttrium-90 radioembolization (RAE) of heavily pretreated patients with colorectal cancer liver metastases (CLM), as well as to create and validate a predictive nomogram for OS. MATERIALS AND METHODS: Metabolic, anatomic, laboratory, pathologic, genetic, primary disease, and procedure-related factors, as well as pre- and post-RAE therapies in 103 patients with CLM treated with RAE from September 15, 2009 to March 21, 2017 were analyzed. LPFS was defined by Response Evaluation Criteria In Solid Tumors 1.1 and European Organization for Research and Treatment of Cancer criteria. Prognosticators of OS and LPFS were selected using univariate Cox regression, adjusted for clustering and competing risk analysis (for LPFS), and subsequently tested in multivariate analysis (MVA). The nomogram was built using R statistical software and internally validated using bootstrap resampling. RESULTS:Patients received RAE at a median of 30.9 months (range, 3.4-161.7 months) after detection of CLM. The median OS and LPFS were 11.3 months (95% confidence interval, 7.9-15.1 months) and 4 months (95% confidence interval, 3.3-4.8 months), respectively. Of the 40 parameters tested, 6 were independently associated with OS in MVA. These baseline parameters included number of extrahepatic disease sites (P < .001), carcinoembryonic antigen (P < .001), albumin (P = .005), alanine aminotransferase level (P < .001), tumor differentiation level (P < .001), and the sum of the 2 largest tumor diameters (P < .001). The 1-year OS of patients with total points of < 25 versus > 80 was 90% and 10%, respectively. Bootstrap resampling showed good discrimination (optimism corrected c-index = 0.745) and calibration (mean absolute prediction error = 0.299) of the nomogram. Only baseline maximum standardized uptake value was significant in MVA for LPFS prediction (P < .001; SHR = 1.06). CONCLUSION: The developed nomogram included 6 pre-RAE parameters and provided good prediction of survival post-RAE in heavily pretreated patients. Baseline maximum standardized uptake value was the single significant predictor of LPFS.
Authors: Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny Journal: J Vasc Interv Radiol Date: 2011-04-22 Impact factor: 3.464
Authors: Robert J Lewandowski; Khairuddin Memon; Mary F Mulcahy; Ryan Hickey; Karen Marshall; Melissa Williams; Krystina Salzig; Vanessa L Gates; Bassel Atassi; Michael Vouche; Rohi Atassi; Kush Desai; Elias Hohlastos; Kent Sato; Ali Habib; Sheetal Kircher; Steven B Newman; Halla Nimeiri; Al B Benson; Riad Salem Journal: Eur J Nucl Med Mol Imaging Date: 2014-06-07 Impact factor: 9.236
Authors: Alain Hendlisz; Marc Van den Eynde; Marc Peeters; Geert Maleux; Bieke Lambert; Jaarke Vannoote; Katrien De Keukeleire; Chris Verslype; Luc Defreyne; Eric Van Cutsem; Philippe Delatte; Thierry Delaunoit; Nicola Personeni; Marianne Paesmans; Jean-Luc Van Laethem; Patrick Flamen Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544
Authors: Wolfgang Peter Fendler; Donfack Beauclair Philippe Tiega; Harun Ilhan; Philipp M Paprottka; Volker Heinemann; Tobias F Jakobs; Peter Bartenstein; Marcus Hacker; Alexander Robert Haug Journal: J Nucl Med Date: 2013-05-31 Impact factor: 10.057
Authors: Constantinos T Sofocleous; Alessandra R Garcia; Neeta Pandit-Taskar; Kinh G Do; Lynn A Brody; Elena N Petre; Marinela Capanu; Anne P Longing; Joanne F Chou; Jorge A Carrasquillo; Nancy E Kemeny Journal: Clin Colorectal Cancer Date: 2013-11-13 Impact factor: 4.035
Authors: D Rohan Jeyarajah; Maria B Majella Doyle; N Joseph Espat; Paul D Hansen; David A Iannitti; Joseph Kim; Thavam Thambi-Pillai; Brendan C Visser Journal: J Gastrointest Oncol Date: 2020-04
Authors: I Kurilova; A Bendet; E K Fung; E N Petre; J L Humm; F E Boas; C H Crane; N Kemeny; T P Kingham; A Cercek; M I D'Angelica; R G H Beets-Tan; C T Sofocleous Journal: Abdom Radiol (NY) Date: 2021-02-19
Authors: Thomas Helmberger; Rita Golfieri; Maciej Pech; Thomas Pfammatter; Dirk Arnold; Roberto Cianni; Geert Maleux; Graham Munneke; Olivier Pellerin; Bora Peynircioglu; Bruno Sangro; Niklaus Schaefer; Niels de Jong; José Ignacio Bilbao Journal: Cardiovasc Intervent Radiol Date: 2020-09-21 Impact factor: 2.740